BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 15638870)

  • 1. Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes.
    Forbes S; Moonan M; Robinson S; Anyaoku V; Patterson M; Murphy KG; Ghatei MA; Bloom SR; Johnston DG
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):51-5. PubMed ID: 15638870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
    Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
    Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
    Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
    Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes.
    Hiroyoshi M; Tateishi K; Yasunami Y; Maeshiro K; Ono J; Matsuoka Y; Ikeda S
    Am J Gastroenterol; 1999 Apr; 94(4):976-81. PubMed ID: 10201468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect.
    Foghsgaard S; Vedtofte L; Andreasen C; Andersen ES; Bahne E; Bagger JI; Svare JA; Holst JJ; Clausen TD; Mathiesen ER; Damm P; Knop FK; Vilsbøll T
    Diabetologia; 2017 Jul; 60(7):1344-1353. PubMed ID: 28364253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection.
    Bendet N; Scapa E; Cohen O; Bloch O; Aharoni D; Ramot Y; Weiss M; Halevi A; Rapoport MJ
    Scand J Gastroenterol; 2004 Jul; 39(7):650-6. PubMed ID: 15370686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of the intravenous and oral glucose tolerance tests for detecting subtle impairments in insulin sensitivity and beta-cell function in former gestational diabetes.
    Tura A; Mari A; Prikoszovich T; Pacini G; Kautzky-Willer A
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):237-43. PubMed ID: 18194489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.
    Lerche S; Soendergaard L; Rungby J; Moeller N; Holst JJ; Schmitz OE; Brock B
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):500-6. PubMed ID: 19094067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF; Nilas L; Madsbad S; Holst JJ
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased high-molecular-weight adiponectin in gestational diabetes: implications for the pathophysiology of Type 2 diabetes.
    Retnakaran R; Connelly PW; Maguire G; Sermer M; Zinman B; Hanley AJ
    Diabet Med; 2007 Mar; 24(3):245-52. PubMed ID: 17305786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.
    Wang Q; Brubaker PL
    Diabetologia; 2002 Sep; 45(9):1263-73. PubMed ID: 12242459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
    Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of fetal hyperinsulinism on oral glucose tolerance test results in patients with gestational diabetes mellitus.
    Weiss PA; Scholz HS; Haas J; Tamussino KF
    Am J Obstet Gynecol; 2001 Feb; 184(3):470-5. PubMed ID: 11228505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.